spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Riquent 

 HSMN NewsFeed - 7 Dec 2010
La Jolla Pharmaceutical Company Announces Appointment of Dr. Bertrand C. Liang to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Sep 2010
La Jolla Pharmaceutical Company Provides Update on Search for Clinical Products to In-License or Acquire
Biopharmaceuticals Licensing
 HSMN NewsFeed - 7 Dec 2009
Adamis Pharmaceuticals Announces Signing of Definitive Merger Agreement
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 7 Dec 2009
La Jolla Pharmaceutical Company Announces Signing of Definitive Merger Agreement With Adamis Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 12 Feb 2009
Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile
Biopharmaceuticals
 HSMN NewsFeed - 12 Feb 2009
La Jolla Pharmaceutical Company Announces Negative Results of Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial
Biopharmaceuticals
 HSMN NewsFeed - 6 Jan 2009
BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent
Biopharmaceuticals
 HSMN NewsFeed - 11 Feb 2008
La Jolla Pharmaceutical Company Reports Progress in International Phase 3 Riquent(R) Study
Biopharmaceuticals
 HSMN NewsFeed - 24 May 2007
La Jolla Pharmaceutical Company Reports Riquent(R) Well Tolerated in Three Studies at International Lupus Congress
Biopharmaceuticals
 HSMN NewsFeed - 10 May 2007
La Jolla Pharmaceutical Company Names Niv Caviar Chief Business and Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Mar 2007
La Jolla Pharmaceutical Provides Update on Interim Antibody Results From Riquent(R) Lupus Phase 3 Trial
Biopharmaceuticals
 HSMN NewsFeed - 8 Mar 2007
La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent(R) Lupus Phase 3 Trial
Biopharmaceuticals
 HSMN NewsFeed - 1 Feb 2007
La Jolla Pharmaceutical Announces Continued Enrollment Progress and Enhancements to International Phase 3 Riquent(R) Study
Biopharmaceuticals
 HSMN NewsFeed - 6 Nov 2006
La Jolla Pharmaceutical Announces Continued Progress With Phase 3 International Riquent(R) Study
Biopharmaceuticals
 HSMN NewsFeed - 12 Oct 2006
La Jolla Pharmaceutical Provides Update on MAA Application in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Sep 2006
La Jolla Pharmaceutical Provides Update on Phase 3 International Riquent(R) Study
Biopharmaceuticals
 HSMN NewsFeed - 9 Aug 2006
La Jolla Pharmaceutical Expands Enrollment in Phase 3 International Riquent(R) Study
Biopharmaceuticals
 HSMN NewsFeed - 17 Jul 2006
Michael Tansey, M.D. Joins La Jolla Pharmaceutical Company as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jun 2006
La Jolla Pharmaceutical Company Files Marketing Authorization Application for European Regulatory Approval of Riquent
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 15 Mar 2006
La Jolla Pharmaceutical Announces Appointment of Deirdre Y. Gillespie as New Chief Executive Officer
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 10

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 10 additional stories matching:
Riquent
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.